Analysts’ Recent Ratings Updates for Progyny (PGNY)

Several analysts have recently updated their ratings and price targets for Progyny (NASDAQ: PGNY):

• 8/21/2026 – Progyny had its price target raised by JPMorgan Chase & Co. from $27.00 to $30.00. They now have a “neutral” rating on the stock.
• 8/20/2026 – Progyny is now covered by Wells Fargo & Company. They set an “overweight” rating and a $37.00 price target on the stock.
• 8/20/2026 – Progyny is now covered by Wells Fargo & Company. They set an “overweight” rating and a $37.00 price target on the stock.
• 8/13/2026 – Progyny was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 8/13/2026 – Progyny had its price target raised by Truist Financial Corporation from $33.00 to $36.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Progyny had its price target lowered by Barclays PLC from $34.00 to $30.00. They now have an “equal weight” rating on the stock.
• 8/7/2026 – Progyny was given a new $35.00 price target by Canaccord Genuity Group Inc..
• 7/28/2026 – Progyny had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $34.00 price target on the stock, up from $27.00.
• 7/28/2026 – Progyny had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $34.00 price target on the stock, up from $27.00.
• 7/25/2026 – Progyny was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 7/24/2026 – Progyny had its price target raised by BTIG Research from $30.00 to $40.00. They now have a “buy” rating on the stock.
• 7/22/2026 – Progyny was given a new $38.00 price target by Leerink Partners.
• 7/21/2026 – Progyny had its price target raised by Canaccord Genuity Group Inc. from $30.00 to $36.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Progyny had its price target raised by KeyCorp from $30.00 to $35.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Progyny was upgraded by Zacks Research from “hold” to “strong-buy”.

Insiders Place Their Bets

In related news, EVP Allison Swartz sold 1,199 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $25.02, for a total transaction of $29,998.98. Following the completion of the sale, the executive vice president owned 83,316 shares in the company, valued at approximately $2,084,566.32. This trade represents a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Mark S. Livingston sold 2,517 shares of Progyny stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $25.50, for a total transaction of $64,183.50. Following the completion of the sale, the chief financial officer directly owned 74,688 shares in the company, valued at approximately $1,904,544. This represents a 3.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 13,563 shares of company stock valued at $351,968. 9.90% of the stock is currently owned by company insiders.

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.